This work investigates the antiradical capacity and potential of Garcinia kola extracts to improve the biochemical markers associated with erectile function and its possible application in clinical treatment. Inhibitory properties of aqueous extract of G. kola on phosphodiesterase-5 (PDE-5), arginase, angiotensin I -converting enzyme (ACE), and acetylcholinesterase (AChE) in rat's genitals tissues were evaluated. Likewise, G. kola extract was explored for reducing power (FRAP) and 1.1-diphenyl-2-picryl-hydrazil (DPPH) radical scavenging abilities. G. kola extract exhibited greater PDE-5 (IC50 = 47.52 ± 0.01 μg/mL), ACE (IC50 = 46.90 ± 0.87 μg/mL), AChE (IC50 = 44.85 ± 1.33 μg/mL) and arginase (IC50 = 47.71 ± 0.25 μg/mL) inhibitory activity in the corpus cavernosum tissue than PDE-5 (IC50 = 75.58 ± 2.04 μg/mL), ACE (IC50 = 53.00 ± 0.30 μg/mL), AChE (IC50 = 54.57 ± 1.50 μg/mL) and arginase (IC50 = 69.68 ± 2.42 μg/mL) inhibitory activity in the testicular tissue homogenate. Furthermore, G. kola exhibited radical scavenging abilities against FRAP and DPPH* radicals. Hence, our results revealed that G. kola extracts are good sources for the development of nutraceuticals and pharmacological properties with attributes to enhance erectile performance.
I N T R O D U C T I O N
Erectile dysfunction (ED) could be described as the problem in attaining or the sustaining erection adequate for sexual performance (1) . Penile erection is defined as a process consisting of a series of reactions, and alteration at any stage of the reactions might damage the whole process (2) . Studies revealed that acetylcholine (ACh) and nitric oxide (NO) perform an important role in the stimulation process (3, 4) . Moreover, elevated activity of arginase decreases the generation of NO, since it breakdowns arginine to urea and ornithine during urea cycle thus decreasing the amount of arginine by NO synthase (5) . Inhibition of AChE is a means in the management of erectile impairment thus controlling the amount of ACh (6) . Oral orthodox medications for managing erectile disfunction are used to facilitate and uphold erection through improving the effect of nitric oxide (7, 8) . Nevertheless, the expensive nature of these orthodox medications for ED has led to the use of traditional herbs by patients in developing countries. Medicinal herbs are employed to enhance sexual performance and treat ED. Medicinal plants such as Massularia acuminata (9) , Tribulus alatus (10) , Spondias mombim (11) , Cnidoscolus aconitefolius (12) have been documented to exhibit aphrodisiac potential.
There are reports that G. kola, a plant cultivated in Africa and distributed globally, exhibited aphrodisiac properties. Generally recognized as bitter kola, this nut is taken as nourishment and are utilized therapeutically for the management of stomach pain, cough, liver disease and erectile impairments (13, 14) in West Africa, Asia, and South America. Because of their bitter flavor, the seeds are employed as a stimulant (15) . They are utilized in the management of hepatic diseases and diarrhea (16) , type 2 diabetes, bronchitis and esophagus infections (17, 18) , and as a natural antimicrobial (19) . G. kola has also been documented to possess ameliorative and aphrodisiac properties (20, 22) . It has also been described to be efficient in the management of skin ailments linked to melanin pigmentation (23) . The objective of this research work was designed to examine potentials of aqueous extract from G. kola to improve the biochemical markers associated with erectile dysfunction and its possible application in clinical treatment.
M A T E R I A L S A ND M E T H O D S
G. kola was procured from a King's market, AdoEkiti in October, 2017. It was authenticated by a taxonomist; voucher number was deposited at Ekiti State University, Nigeria. G. kola was dried and pulverized in a blender. The fine particles obtained weighing 88 g were macerated in 880 mL distilled water for 24 h as described by Ojo et al. (24) The extract was filtered, and the subsequent filtrate was concentrated to yield 45.25 g of the residue.
CHEMICALS AND REAGENTS
Unless otherwise stated, all chemicals and reagents used were of analytical grades. A UV-visible spectrophotometer was used to measure absorbance.
EXPERIMENTAL ANIMALS
Twenty male Wistar rats (weighing between 270 and 290 g) were obtained from Animal holding house of Department of Biochemistry and were handled in agreement to the guide for Maintenance and Usage of Experimental Animals formulated by the National Academy of Science, issued by the National Institutes of Health (USA). Animals were made to acclimatize for two weeks and under standard conditions. The ethical guidelines were followed with approval number (18/ABUAD/067).
Preparation of penile and testicular homogenate
Experiment rats were placed under ether anesthesia and euthanized by cervical dislocation, then tissue samples were harvested. The erectile organ (penis and testes) were removed, washed and weighed. Tissues were homogenized in normal saline (1/10 w/v) at approximately 1200 rev/min for 10 min at 3000 ×g to produce a residue that was removed and the supernatant was reserved for inhibitory enzyme assay.
Phosphodiesterase-5 (PDE-5) inhibitory activity
Inhibition PDE-5 activity was estimated by Oboh et al. (25) . The enzymatic solution comprising 5 mM of the substrate (p-nitrophenyl phenyl phosphonate), (penis and testes) supernatant, Tris buffer (pH 8.0) and the aqueous extracts of G. kola were placed on a steam bath at 37 °C for 15 min. The amount of p-nitro phenol generation was read as a variation in absorbance after 5 min at a wavelength of 400 nm. Control was achieved minus the extracts/Sildenafil. PDE-5 inhibitory enzyme activity was calculated as:
PDE -5 inhibition (%) = [(Abs control -Abs samples) / Abs control] x 100
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Arginase inhibitory activity
Erectile organ homogenates (penis and testes) were made by homogenizing 10 g (w/v) in cold sodium phosphate buffer (pH 7.2). The homogenized tissues were centrifuged for 20 min at 4000 r.p.m and the supernatant was used as enzyme source. Arginase activity was evaluated via the amount of urea generated via Ehrlich's reagent. The solution comprised the totalvolume of 1.0 mM Tris-HCl buffer pH 9.5, MnCl, arginine solution, and G. kola extracts /L-2-amino-[4-(20-hydroxyguanidino)] butyric acid (L-NOHA). The reaction process was placed on a steam bath for 15 min at 37 °C and stopped via the addition of 2.5 mL Ehrlich reagent. Absorbance was read after 20 min at 450 nm wavelength and inhibitory activity was expressed as percent inhibition (26) .
Acetylcholinesterase activity assay
Erectile organ (penis and testes) was homogenized in cold sodium phosphate buffer (pH 7.2) and homogenate was employed as the enzyme source. The inhibitory potentials of the aqueous extracts of G. kola and standard drug prostigmine on AChE activity were estimated as described by Tel et al. (27) with little adjustments. Acetylcholinesterase activity was estimated in the solution comprising tissue homogenate as the enzyme source, 5,5-dithiol-bis (2-nitrobenzoic) acid (DTNB) and G. kola extracts. This was placed on a steam bathtub for 15 min at 25 °C, and the substrate was added. Absorbance was read at 412 nm. AChE activity was calculated as percentage inhibition.
Angiotensin-I-Converting Enzyme (ACE) inhibitory activity
Inhibition of the ACE activity of aqueous extracts of G. kola was estimated following the protocol of Cushman and Cheung (28) . Concentrations of the extracts, reference drug lisinopril and organ homogenate (penis and testes) as a source of the ACE enzyme (4 mU/mL) were pre-incubated at 37 °C for 10 min. Afterwards, the process was started via the addition of 200 L of 8.33mM ACE substrate in 125 mM of Tris-HCl buffer (pH 8.3) to the solution and steam bath at 37 °C for 20 min. The process was terminated with the addition of 300 L of 1M hydrochloric acid. The hippuric acid (Bz-Gly) generated through the process was removed by adding 2 mL ethyl acetate and further centrifuged to decant the ethyl acetate layer and transferred to a volumetric flask for evaporating to dryness. Absorbance was read at 228 nm. Control was done without the aqueous extract or standard drug lisinopril. ACE percentage inhibition was then calculated in equation.
DETERMINATION OF ANTIOXIDANT ACTIVITIES

Ferric reducing antioxidant ability
Reducing power of the aqueous extract of G. kola was estimated via the reduction of the FeCl3 solution by Pulido et al. (29) . Three mL of 200 mM phosphate buffer (pH 6.6) and 3 mL of 1% potassium ferricyanide were added to the extract. The resulting solution was placed on a steam bath for 20 min at 50 °C and reaction was stopped by adding 3 mL of 10% TCA. The obtained sample was centrifuged at 650 g for 10 min and 5 mL of the supernatant was added to an equivalent volume of water and 1.0 mL, 0.1% FeCl3. Absorbance was read at 700 nm. Reducing power was expressed in ascorbic acid equivalent (AAE).
Free radical scavenging ability
Free radical scavenging ability of the aqueous extract against DPPH* was measured via the protocol described by Ojo et al. (30) . Concisely, a suitable solution of the aqueous extract (2 mL) was added to 1 mL 0.4 mM DPPH solution in methanol. The solution was kept in the dark for 30 min, and the absorbance was read at 516 nm. DPPH* scavenging ability was estimated with deference to the control (sample without extract) and the standard drug used for assessing DPPH activity was vitamin C. DPPH* scavenging ability (%) = [(Abs controlAbs sapmles)/Abs control] × 100
Data analysis
Data are presented as the mean ± SD (n = 3). The data were analyzed by one-way analysis of variance via a statistical software package (SPSS, Version 20.0, IBM Corporation, NY, USA) one-way ANOVA using Duncan multiple range post-hoc test (DMRT). These analyses were performed with Graph-Pad Prism for Windows version 5.0. Values were considered to be significantly different at p < 0.05. 
R E S U L T S
Phosphodiesterase-5 activities (PDE-5) of aqueous extract of G. kola in rats' genitals were estimated and presented in Figure 1A .
The result exhibited by the aqueous extract of G. kola inhibited PDE-5 enzymes. With regards to the IC50 presented in Table 1 , it demonstrated that extracts exhibited greater inhibitory activity on corpus cavernosum phosphodiesterase-5 (IC50 = 47.52 ± 0.01μg/mL) than testicular phosphodiesterase-5 (IC50 = 75.58 ± 2.04 μg/mL). Nevertheless, sildenafil had the utmost activity as shown by the IC50 (26.65 ± 0.10 μg/mL). Arginase inhibitory activity by the aqueous extract of G. kola is given in Figure 1B . The extracts inhibited arginase activity in rats' genitals in all tested concentrations, although, IC50 suggested that G. kola extracts had a greater inhibitory activity on corpus cavernosum arginase (47.71 ± 0.25 μg/mL) than testicular arginase (69.68 ± 2.42 μg/mL). Nevertheless, L-NOHA had the highest inhibitory activity as shown by IC50 (42.48 ± 0.21 μg/mL). Figure 1C displayed the inhibitory activity of G. kola extracts on acetylcholinesterase (AChE) enzyme. AChE activity was inhibited by aqueous extract of G. kola in all tested concentrations. Therefore, G. kola extracts had a better inhibitory activity on corpus cavernosum AChE activity (IC50 = 44.85 ± 1.33 μg/mL) than testicular AChE activity (IC50 = 54.57 ± 1.50 μg/mL). Figure 1D displayed the inhibitory ACE activity by G. kola extracts in rats' genitals. ACE activity was inhibited by both G. kola extracts and lisinopril, though G. kola extracts had a better inhibitory activity on corpus cavernosum (IC50 = 46.90 ± 0.87 μg/mL) than testicular ACE (IC50 = 53.00 ± 0.30 μg/mL) activity as shown by their IC50 values. Table 1 revealed the ferric reducing ability of G. kola extracts. The result revealed that the extracts had a reducing property of (58.65 ± 1.45 mg/g AAE). Figure 1E revealed the ability of the leaf aqueous extract of G. kola to scavenge DPPH* in rats' genitals. G. kola extracts were able to scavenge radicals generated by DPPH*, though, vitamin C scavenge DPPH* better than the G. kola extracts, as revealed by their IC50 values.
D I S C U S S I O N
Phosphodiesterase-5′ is an enzyme contained in rats' genitals and performs a key function in corpus cavernosum weakness, inhibition of the platelets and dilation of blood vessels (31) . The observed inhibitory activities of PDE-5 by G. kola indicate that G. kola extracts contain active principles with therapeutic attributes for managing ED, resulting in the elevation of cellular concentrations of cyclic-guanosine monophosphate (cGMP) in rats' genitals thus improving blood vessels dilation and smooth muscle relaxation. The biosynthesis of NO and its availability may reduce due to the increased activity or overexpression of arginase enzyme (32) . Current examinations have acknowledged arginase as a marker in managing sexual disorders (33, 34) leading to upregulation of arginase activity and reduced nitric oxide levels in the penile tissues. In ED, reduced NO are documented owing to improved arginase activities, changing the expression of endothelial NO synthase (eNOS) (35) . Nevertheless, it is important to note that arginase inhibition by the G. kola seed extracts may possibly be an alternative route of increasing the appearance and activities of eNOS, thus raising the bioavailability of nitric oxide. Hence, inhibitory properties of the G. kola extracts on arginase might be ascribed to their phenolic and flavonoids components such as catechin, chromanols, garcinoic acid, garcinial and d-tocotrienol (Figure 2 ) isolated by Farombi (36) . This is in correlation with the report of (11, 12 ) that phenolics and flavonoids compounds of a plant are responsible for the improvement of erectile function.
Studies have documented that cholinergic enzymes in rat's genitals discharge ACh for the activation of nitric oxide production from L-arginine via NO synthase for sexual performance to occur through powering of erectile function (6, 37, 38) . The inhibition of the enzyme in rat's genital tissue suggests that G. kola seed extracts might be a leading plant with beneficial attributes in the management of ED. Thus, the inhibitory activity of AChE by the G. kola extracts might be linked to the occurrence of flavonoids and phenolic compounds, which corroborates with previous reports that herbs reach in phenols might inhibit AChE (12, 39, 40, 41) .
Hypertension, a key causative agent of erectile disfunction has been associated with angiotensin (12, 42) . ACE inhibition results in the prevention of angiotensin synthesis, thus remaining a remedial point in managing hypertensive-induced ED, thus, hindering the production of angiotensin II in rat's genitals which could possibly be helpful in the treatment of ED. Moreover, flavonoids and phenols are documented to be strong inhibitors of ACE activity (43, 44) , and may possibly be accountable for the greater inhibitory effect displayed by G. kola extracts. Therefore, this study showed that G. kola extracts inhibited ACE activity, subsequently decreasing angiotensin II levels in rat's genitals which could be due to the interactions between the phenolic and flavonoids present in the leaves and disulphidebridge of the enzyme (36, 42, 45, 46) .
Total reducing property of a plant serves as an important pointer of its antiradical properties. Free radicals are known to be an important factor of cellular damage in the biological system, and DPPH are utilized to evaluate the radical scavenging ability of natural antioxidants (46, 47) . All these radicals are involved in the pathogenesis of several disorders such as erectile dysfunction. Hence, findings from this investigation have shown that G. kola extracts possessed antioxidant activity having reasonable scavenging activity towards the various forms of radicals (48, 49) .
C O N C L U S I O N
This study revealed that G. kola extracts exhibited inhibitory properties on enzyme activities involved in erectile function and displayed radical scavenging abilities which might be connected to their phenolic and flavornoids components. Enzyme inhibitory potentials and antiradical properties of G. kola extracts indicate their attributes as nutraceuticals and/or pharmaceuticals in managing ED.
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